R&D-driven biotech company Ascletis Pharma Inc (HKEX:1672) is conducting a novel coronavirus pneumonia clinical trial of oral Ganovo and Ritonavir combination therapy, the company announced on Wednesday.
Following approval from the ethics committee of the Ninth Hospital of Nanchang, the first patient diagnosed with novel coronavirus pneumonia was treated with the Ganovo and Ritonavir combination therapy on 17 February 2020.
Three treated patients have now been discharged from the hospital after meeting the discharge standards under the Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6) issued by China's National Health Commission, and other enrolled patients are being treated.
Ganovo is an oral Hepatitis C virus (HCV) protease inhibitor. It was approved by the National Medical Products Administration for market launch in June 2018.
An article, 'Therapeutic options for the 2019 novel coronavirus (2019-nCoV)', published by British magazine Nature Reviews Drug Discovery on 10 February 2020, suggests that existing anti-HIV and anti-HCV drugs may have inhibitory effects against novel coronavirus, the company noted.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results